Shionogi, Inc
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1919-01-01
- Employees
- -
- Market Cap
- $13.1B
Clinical Trials
72
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (68 trials with phase data)• Click on a phase to view related trials
Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 32
- Registration Number
- NCT07018492
- Locations
- 🇺🇸
Division of Clinical Pharmacology, University of Miami, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸American Research Corporation dba Texas Liver Institute, San Antonio, Texas, United States
Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls
- First Posted Date
- 2025-06-10
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 16
- Registration Number
- NCT07012005
- Locations
- 🇺🇸
Division of Clinical Pharmacology, University of Miami, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Clinical Trials for Texas, LLC, dba Flourish Research, San Antonio, Texas, United States
A Study to Assess the Effects of BPN14770 on Rosuvastatin
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2025-06-10
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 14
- Registration Number
- NCT07011992
A Study of S-892216 in Participants With COVID-19
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 280
- Registration Number
- NCT06928051
- Locations
- 🇺🇸
Healthstar Research, Hot Springs, Arkansas, United States
🇺🇸Palm Springs Community Health Center, Miami Lakes, Florida, United States
🇺🇸Quality Research of South Florida, Miami Lakes, Florida, United States
A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants
- First Posted Date
- 2025-01-15
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 24
- Registration Number
- NCT06775730
- Locations
- 🇺🇸
Early Phase Clinical Unit Los Angeles, Glendale, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 15
- Next
News
ViiV Healthcare Presents Real-World Data on Long-Acting HIV Treatments at IAS 2025
ViiV Healthcare presented extensive real-world data at IAS 2025 demonstrating the effectiveness, safety, and tolerability of its long-acting injectable HIV treatments, including cabotegravir + rilpivirine LA for treatment and cabotegravir LA for prevention.
Stallergenes Greer Transitions Actair® Promotional Activities from Shionogi to CEOLIA in Japan
Stallergenes Greer has appointed CEOLIA Pharma as its new promotional partner for Actair® in Japan, ending a 15-year licensing agreement with Shionogi that began in 2010.
BioVersys and Shionogi Form Strategic Partnership to Develop Novel NTM Treatments Worth Up to CHF 484 Million
BioVersys and Shionogi have entered a research collaboration and exclusive license option agreement to develop novel ansamycin leads from BioVersys' BV500 program targeting non-tuberculous mycobacteria infections.
Shionogi and Cilcare Partner in €400M Deal to Develop Novel Hearing Loss Treatments
Shionogi has entered into a joint research agreement with Cilcare to develop innovative treatments for hearing loss, a condition affecting 5% of the global population with no effective treatments currently available.
Shionogi to Acquire Japan Tobacco's Pharma Units for $1.1 Billion
Japanese pharmaceutical company Shionogi has announced a $1.1 billion acquisition of Torii Pharmaceutical and other pharmaceutical assets from Japan Tobacco, marking a significant consolidation in the Japanese pharma sector.
F2G's Novel Antifungal Olorofim Shows Promise Despite FDA Setback, Phase 2b Results Published in The Lancet
F2G's olorofim, the first in a new class of orotomide antifungals, received a complete response letter from the FDA requiring additional data before approval.
Cefiderocol Shows Higher Efficacy When Used Earlier in Treatment of Serious Gram-Negative Infections
New data from the PROVE study reveals cefiderocol achieves better clinical outcomes when used as empiric (64.6%) or documented therapy (67.4%) compared to salvage therapy (58.2%) in serious gram-negative infections.
Ensitrelvir Shows 67% Reduction in COVID-19 Risk as First Effective Post-Exposure Prophylaxis in Phase 3 Trial
Shionogi's SCORPIO-PEP Phase 3 trial demonstrated ensitrelvir reduces COVID-19 risk by 67% in exposed household contacts, making it the first oral antiviral to successfully prevent COVID-19 after exposure.
ViiV Healthcare's N6LS Broadly Neutralizing Antibody Shows Promise in HIV Long-Acting Treatment
Phase IIb EMBRACE study demonstrates N6LS (VH109), administered every four months with monthly cabotegravir, successfully maintained viral suppression in 96% of participants receiving intravenous treatment.
ViiV Healthcare Showcases Long-Acting HIV Innovations and Pipeline Advances at CROI 2025
Real-world data presented at CROI 2025 demonstrates zero HIV acquisitions and high persistence with Apretude (cabotegravir LA) for PrEP across diverse populations, reinforcing its effectiveness in HIV prevention.